



THE HARVARD DRUG GROUP^{LLC}
your strongest ally

Dear Valued Customer,

We want to continue to keep you informed on our efforts to work with the DEA to help combat an industry wide problem.

You may be aware that on Tuesday, June 15, the U.S. Drug Enforcement Administration suspended the license of our Livonia, Michigan distribution facility, alleging insufficient control of the identification of orders emanating from customers licensed by the DEA and State Boards of Pharmacy, who are nevertheless engaged in or likely to be engaged in suspicious, potentially illegal activity. I want to advise you that on the morning of June 16, our attorneys filed a Complaint for Declaratory and Injunctive Relief against the DEA in Federal Court.

I am pleased to let you know that today, June 18, the DEA and Harvard Drug Group jointly announced an agreement to immediately lift the suspension as to class III through V controlled drugs and a mutual commitment to commence discussions towards resolution of the remaining issues raised by the DEA.

As a result, Harvard has withdrawn its request for a Temporary Restraining Order and our Complaint for Declaratory and Injunctive Relief, while we engage in these discussions. Our agreement with the DEA is an important first step in taking actions that will result in an even safer and more secure pharmaceutical supply chain. We are pleased to have the opportunity to work closely with the DEA not only to improve the work we do at Harvard, but indirectly help our industry do better.

We remain fully responsible and committed to you, our customers and the public.

We will recommence the sale of class III thru V controlled drugs starting next week. We will voluntarily stop shipping class II controlled drugs while we are resolving the remaining issues with the DEA, which we trust will not take too long.

We take our responsibility as your distributor very seriously. It is business as usual. Our employees nationwide will continue to provide you with seamless service. We make our living fulfilling the needs of our customers. That's our job.

I will continue to keep you informed of our progress. Thank you for your understanding and support.

Regards,

Randolph Friedman

Randolph Friedman, Chairman and Chief Executive Officer
The Harvard Drug Group, LLC